These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 18614364

  • 1. Discovery of imidazole carboxamides as potent and selective CCK1R agonists.
    Zhu C, Hansen AR, Bateman T, Chen Z, Holt TG, Hubert JA, Karanam BV, Lee SJ, Pan J, Qian S, Reddy VB, Reitman ML, Strack AM, Tong V, Weingarth DT, Wolff MS, MacNeil DJ, Weber AE, Duffy JL, Edmondson SD.
    Bioorg Med Chem Lett; 2008 Aug 01; 18(15):4393-6. PubMed ID: 18614364
    [Abstract] [Full Text] [Related]

  • 2. 2-Substituted piperazine-derived imidazole carboxamides as potent and selective CCK1R agonists for the treatment of obesity.
    Berger R, Zhu C, Hansen AR, Harper B, Chen Z, Holt TG, Hubert J, Lee SJ, Pan J, Qian S, Reitman ML, Strack AM, Weingarth DT, Wolff M, Macneil DJ, Weber AE, Edmondson SD.
    Bioorg Med Chem Lett; 2008 Sep 01; 18(17):4833-7. PubMed ID: 18684621
    [Abstract] [Full Text] [Related]

  • 3. Discovery of pyrimidine carboxamides as potent and selective CCK1 receptor agonists.
    Wang L, Hubert JA, Lee SJ, Pan J, Qian S, Reitman ML, Strack AM, Weingarth DT, MacNeil DJ, Weber AE, Edmondson SD.
    Bioorg Med Chem Lett; 2011 May 15; 21(10):2911-5. PubMed ID: 21493064
    [Abstract] [Full Text] [Related]

  • 4. Discovery of novel orally active ureido NPY Y5 receptor antagonists.
    Li G, Stamford AW, Huang Y, Cheng KC, Cook J, Farley C, Gao J, Ghibaudi L, Greenlee WJ, Guzzi M, van Heek M, Hwa JJ, Kelly J, Mullins D, Parker EM, Wainhaus S, Zhang X.
    Bioorg Med Chem Lett; 2008 Feb 01; 18(3):1146-50. PubMed ID: 18160282
    [Abstract] [Full Text] [Related]

  • 5. 1-Sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists for the treatment of obesity.
    Vachal P, Fletcher JM, Fong TM, Huang CC, Lao J, Xiao JC, Shen CP, Strack AM, Shearman L, Stribling S, Chen RZ, Frassetto A, Tong X, Wang J, Ball RG, Tsou NN, Hickey GJ, Thompson DF, Faidley TD, Nicolich S, Achanfuo-Yeboah J, Hora DF, Hale JJ, Hagmann WK.
    J Med Chem; 2009 Apr 23; 52(8):2550-8. PubMed ID: 19320488
    [Abstract] [Full Text] [Related]

  • 6. Antiobesity designed multiple ligands: Synthesis of pyrazole fatty acid amides and evaluation as hypophagic agents.
    Alvarado M, Goya P, Macías-González M, Pavón FJ, Serrano A, Jagerovic N, Elguero J, Gutiérrez-Rodríguez A, García-Granda S, Suardíaz M, Rodríguez de Fonseca F.
    Bioorg Med Chem; 2008 Dec 01; 16(23):10098-105. PubMed ID: 18952442
    [Abstract] [Full Text] [Related]

  • 7. Identification of piperazine-bisamide GHSR antagonists for the treatment of obesity.
    Yu M, Lizarzaburu M, Beckmann H, Connors R, Dai K, Haller K, Li C, Liang L, Lindstrom M, Ma J, Motani A, Wanska M, Zhang A, Li L, Medina JC.
    Bioorg Med Chem Lett; 2010 Mar 01; 20(5):1758-62. PubMed ID: 20137933
    [Abstract] [Full Text] [Related]

  • 8. Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists.
    Szabó G, Varga B, Páyer-Lengyel D, Szemzo A, Erdélyi P, Vukics K, Szikra J, Hegyi E, Vastag M, Kiss B, Laszy J, Gyertyán I, Fischer J.
    J Med Chem; 2009 Jul 23; 52(14):4329-37. PubMed ID: 19527048
    [Abstract] [Full Text] [Related]

  • 9. SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. II. In vivo pharmacological characterization.
    Bignon E, Alonso R, Arnone M, Boigegrain R, Brodin R, Gueudet C, Héaulme M, Keane P, Landi M, Molimard JC, Olliero D, Poncelet M, Seban E, Simiand J, Soubrié P, Pascal M, Maffrand JP, Le Fur G.
    J Pharmacol Exp Ther; 1999 May 23; 289(2):752-61. PubMed ID: 10215649
    [Abstract] [Full Text] [Related]

  • 10. Synthesis and evaluation of alkoxy-phenylamides and alkoxy-phenylimidazoles as potent sphingosine-1-phosphate receptor subtype-1 agonists.
    Evindar G, Bernier SG, Kavarana MJ, Doyle E, Lorusso J, Kelley MS, Halley K, Hutchings A, Wright AD, Saha AK, Hannig G, Morgan BA, Westlin WF.
    Bioorg Med Chem Lett; 2009 Jan 15; 19(2):369-72. PubMed ID: 19081720
    [Abstract] [Full Text] [Related]

  • 11. Discovery of 5-phenoxy-1,3-dimethyl-1H-pyrazole-4-carboxamides as potent agonists of TGR5 via sequential combinatorial libraries.
    Londregan AT, Piotrowski DW, Futatsugi K, Warmus JS, Boehm M, Carpino PA, Chin JE, Janssen AM, Roush NS, Buxton J, Hinchey T.
    Bioorg Med Chem Lett; 2013 Mar 01; 23(5):1407-11. PubMed ID: 23337601
    [Abstract] [Full Text] [Related]

  • 12. Synthesis and evaluation of 5,5-diphenylimidazolones as potent human neuropeptide Y5 receptor antagonists.
    Gillman KW, Higgins MA, Poindexter GS, Browning M, Clarke WJ, Flowers S, Grace JE, Hogan JB, McGovern RT, Iben LG, Mattson GK, Ortiz A, Rassnick S, Russell JW, Antal-Zimanyi I.
    Bioorg Med Chem; 2006 Aug 15; 14(16):5517-26. PubMed ID: 16697206
    [Abstract] [Full Text] [Related]

  • 13. Discovery of biological evaluation of pyrazole/imidazole amides as mGlu5 receptor negative allosteric modulators.
    Chae E, Shin YJ, Ryu EJ, Ji MK, Ryune Cho N, Lee KH, Jeong HJ, Kim SJ, Choi Y, Seok Oh K, Park CE, Soo Yoon Y.
    Bioorg Med Chem Lett; 2013 Apr 01; 23(7):2134-9. PubMed ID: 23434029
    [Abstract] [Full Text] [Related]

  • 14. Novel selective neuropeptide Y2 receptor PEGylated peptide agonists reduce food intake and body weight in mice.
    Lumb KJ, DeCarr LB, Milardo LF, Mays MR, Buckholz TM, Fisk SE, Pellegrino CM, Ortiz AA, Mahle CD.
    J Med Chem; 2007 May 03; 50(9):2264-8. PubMed ID: 17425299
    [Abstract] [Full Text] [Related]

  • 15. The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity.
    Hagmann WK.
    Arch Pharm (Weinheim); 2008 Jul 03; 341(7):405-11. PubMed ID: 18574849
    [Abstract] [Full Text] [Related]

  • 16. Discovery and pharmacological evaluation of growth hormone secretagogue receptor antagonists.
    Xin Z, Serby MD, Zhao H, Kosogof C, Szczepankiewicz BG, Liu M, Liu B, Hutchins CW, Sarris KA, Hoff ED, Falls HD, Lin CW, Ogiela CA, Collins CA, Brune ME, Bush EN, Droz BA, Fey TA, Knourek-Segel VE, Shapiro R, Jacobson PB, Beno DW, Turner TM, Sham HL, Liu G.
    J Med Chem; 2006 Jul 27; 49(15):4459-69. PubMed ID: 16854051
    [Abstract] [Full Text] [Related]

  • 17. Synthesis and SAR of heterocyclic carboxylic acid isosteres based on 2-biarylethylimidazole as bombesin receptor subtype-3 (BRS-3) agonists for the treatment of obesity.
    Hadden M, Goodman A, Guo C, Guzzo PR, Henderson AJ, Pattamana K, Ruenz M, Sargent BJ, Swenson B, Yet L, Liu J, He S, Sebhat IK, Lin LS, Tamvakopoulos C, Peng Q, Kan Y, Palyha O, Kelly TM, Guan XM, Metzger JM, Reitman ML, Nargund RP.
    Bioorg Med Chem Lett; 2010 May 01; 20(9):2912-5. PubMed ID: 20347296
    [Abstract] [Full Text] [Related]

  • 18. N-(3-(phenylcarbamoyl)arylpyrimidine)-5-carboxamides as potent and selective inhibitors of Lck: structure, synthesis and SAR.
    Deak HL, Newcomb JR, Nunes JJ, Boucher C, Cheng AC, DiMauro EF, Epstein LF, Gallant P, Hodous BL, Huang X, Lee JH, Patel VF, Schneider S, Turci SM, Zhu X.
    Bioorg Med Chem Lett; 2008 Feb 01; 18(3):1172-6. PubMed ID: 18083554
    [Abstract] [Full Text] [Related]

  • 19. Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
    Lin LS, Lanza TJ, Jewell JP, Liu P, Shah SK, Qi H, Tong X, Wang J, Xu SS, Fong TM, Shen CP, Lao J, Xiao JC, Shearman LP, Stribling DS, Rosko K, Strack A, Marsh DJ, Feng Y, Kumar S, Samuel K, Yin W, Van der Ploeg LH, Goulet MT, Hagmann WK.
    J Med Chem; 2006 Dec 28; 49(26):7584-7. PubMed ID: 17181138
    [Abstract] [Full Text] [Related]

  • 20. Discovery of 2-[5-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H-pyrazol-3-yl]-1,5,5-trimethyl-1,5-dihydro-imidazol-4-thione (BPR-890) via an active metabolite. A novel, potent and selective cannabinoid-1 receptor inverse agonist with high antiobesity efficacy in DIO mice.
    Wu CH, Hung MS, Song JS, Yeh TK, Chou MC, Chu CM, Jan JJ, Hsieh MT, Tseng SL, Chang CP, Hsieh WP, Lin Y, Yeh YN, Chung WL, Kuo CW, Lin CY, Shy HS, Chao YS, Shia KS.
    J Med Chem; 2009 Jul 23; 52(14):4496-510. PubMed ID: 19530697
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.